Intrinsic value of Eagle Pharmaceuticals - EGRX

Previous Close

$52.94

  Intrinsic Value

$1,190

stock screener

  Rating & Target

str. buy

+999%

  Value-price divergence*

0%

Previous close

$52.94

 
Intrinsic value

$1,190

 
Up/down potential

+999%

 
Rating

str. buy

 
Value-price divergence*

0%

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of EGRX stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2016), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.8

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  186.36
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  189
  302
  467
  699
  1,014
  1,430
  1,966
  2,639
  3,466
  4,460
  5,633
  6,995
  8,552
  10,308
  12,264
  14,420
  16,774
  19,322
  22,061
  24,985
  28,091
  31,374
  34,830
  38,458
  42,256
  46,223
  50,359
  54,666
  59,148
  63,808
  68,651
Variable operating expenses, $m
 
  175
  268
  399
  578
  813
  1,117
  1,497
  1,965
  2,527
  3,191
  3,958
  4,839
  5,832
  6,939
  8,159
  9,491
  10,933
  12,483
  14,137
  15,895
  17,752
  19,708
  21,761
  23,910
  26,154
  28,495
  30,932
  33,468
  36,105
  38,845
Fixed operating expenses, $m
 
  27
  27
  28
  29
  29
  30
  31
  32
  32
  33
  34
  35
  36
  37
  38
  39
  40
  41
  42
  43
  44
  45
  46
  47
  48
  49
  51
  52
  53
  55
Total operating expenses, $m
  136
  202
  295
  427
  607
  842
  1,147
  1,528
  1,997
  2,559
  3,224
  3,992
  4,874
  5,868
  6,976
  8,197
  9,530
  10,973
  12,524
  14,179
  15,938
  17,796
  19,753
  21,807
  23,957
  26,202
  28,544
  30,983
  33,520
  36,158
  38,900
Operating income, $m
  53
  101
  172
  271
  407
  588
  820
  1,111
  1,469
  1,900
  2,408
  3,003
  3,678
  4,439
  5,288
  6,223
  7,244
  8,350
  9,538
  10,806
  12,153
  13,578
  15,077
  16,651
  18,299
  20,020
  21,815
  23,684
  25,628
  27,650
  29,751
EBITDA, $m
  55
  106
  178
  279
  417
  599
  834
  1,129
  1,491
  1,927
  2,441
  3,039
  3,722
  4,493
  5,351
  6,298
  7,331
  8,450
  9,652
  10,935
  12,299
  13,740
  15,258
  16,851
  18,518
  20,259
  22,075
  23,967
  25,934
  27,980
  30,107
Interest expense (income), $m
  0
  0
  1
  3
  6
  10
  14
  21
  29
  38
  50
  63
  79
  97
  118
  141
  166
  193
  223
  255
  289
  325
  364
  404
  446
  490
  537
  585
  635
  687
  742
Earnings before tax, $m
  53
  101
  170
  268
  402
  578
  805
  1,090
  1,440
  1,862
  2,358
  2,939
  3,598
  4,342
  5,170
  6,082
  7,078
  8,156
  9,314
  10,551
  11,864
  13,252
  14,714
  16,248
  17,853
  19,530
  21,278
  23,099
  24,993
  26,963
  29,010
Tax expense, $m
  -28
  27
  46
  72
  108
  156
  217
  294
  389
  503
  637
  794
  972
  1,172
  1,396
  1,642
  1,911
  2,202
  2,515
  2,849
  3,203
  3,578
  3,973
  4,387
  4,820
  5,273
  5,745
  6,237
  6,748
  7,280
  7,833
Net income, $m
  81
  73
  124
  196
  293
  422
  588
  796
  1,052
  1,359
  1,722
  2,146
  2,627
  3,170
  3,774
  4,440
  5,167
  5,954
  6,800
  7,702
  8,661
  9,674
  10,741
  11,861
  13,033
  14,257
  15,533
  16,862
  18,245
  19,683
  21,177

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  53
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  214
  258
  398
  595
  864
  1,218
  1,675
  2,248
  2,952
  3,799
  4,798
  5,958
  7,284
  8,780
  10,446
  12,283
  14,288
  16,459
  18,791
  21,282
  23,927
  26,724
  29,668
  32,758
  35,993
  39,372
  42,895
  46,564
  50,382
  54,351
  58,476
Adjusted assets (=assets-cash), $m
  161
  258
  398
  595
  864
  1,218
  1,675
  2,248
  2,952
  3,799
  4,798
  5,958
  7,284
  8,780
  10,446
  12,283
  14,288
  16,459
  18,791
  21,282
  23,927
  26,724
  29,668
  32,758
  35,993
  39,372
  42,895
  46,564
  50,382
  54,351
  58,476
Revenue / Adjusted assets
  1.174
  1.171
  1.173
  1.175
  1.174
  1.174
  1.174
  1.174
  1.174
  1.174
  1.174
  1.174
  1.174
  1.174
  1.174
  1.174
  1.174
  1.174
  1.174
  1.174
  1.174
  1.174
  1.174
  1.174
  1.174
  1.174
  1.174
  1.174
  1.174
  1.174
  1.174
Average production assets, $m
  19
  31
  47
  71
  102
  144
  199
  267
  350
  450
  569
  706
  864
  1,041
  1,239
  1,456
  1,694
  1,952
  2,228
  2,523
  2,837
  3,169
  3,518
  3,884
  4,268
  4,668
  5,086
  5,521
  5,974
  6,445
  6,934
Working capital, $m
  68
  24
  37
  55
  80
  113
  155
  209
  274
  352
  445
  553
  676
  814
  969
  1,139
  1,325
  1,526
  1,743
  1,974
  2,219
  2,479
  2,752
  3,038
  3,338
  3,652
  3,978
  4,319
  4,673
  5,041
  5,423
Total debt, $m
  0
  38
  93
  170
  275
  413
  592
  816
  1,091
  1,422
  1,813
  2,267
  2,785
  3,370
  4,022
  4,740
  5,524
  6,372
  7,284
  8,258
  9,293
  10,386
  11,537
  12,746
  14,010
  15,331
  16,709
  18,144
  19,636
  21,188
  22,801
Total liabilities, $m
  63
  101
  156
  233
  338
  476
  655
  879
  1,154
  1,485
  1,876
  2,330
  2,848
  3,433
  4,085
  4,803
  5,587
  6,435
  7,347
  8,321
  9,356
  10,449
  11,600
  12,809
  14,073
  15,394
  16,772
  18,207
  19,699
  21,251
  22,864
Total equity, $m
  151
  157
  242
  362
  526
  742
  1,020
  1,369
  1,798
  2,313
  2,922
  3,628
  4,436
  5,347
  6,362
  7,480
  8,701
  10,023
  11,444
  12,961
  14,572
  16,275
  18,068
  19,950
  21,920
  23,977
  26,123
  28,358
  30,682
  33,100
  35,612
Total liabilities and equity, $m
  214
  258
  398
  595
  864
  1,218
  1,675
  2,248
  2,952
  3,798
  4,798
  5,958
  7,284
  8,780
  10,447
  12,283
  14,288
  16,458
  18,791
  21,282
  23,928
  26,724
  29,668
  32,759
  35,993
  39,371
  42,895
  46,565
  50,381
  54,351
  58,476
Debt-to-equity ratio
  0.000
  0.240
  0.380
  0.470
  0.520
  0.560
  0.580
  0.600
  0.610
  0.610
  0.620
  0.620
  0.630
  0.630
  0.630
  0.630
  0.630
  0.640
  0.640
  0.640
  0.640
  0.640
  0.640
  0.640
  0.640
  0.640
  0.640
  0.640
  0.640
  0.640
  0.640
Adjusted equity ratio
  0.609
  0.609
  0.609
  0.609
  0.609
  0.609
  0.609
  0.609
  0.609
  0.609
  0.609
  0.609
  0.609
  0.609
  0.609
  0.609
  0.609
  0.609
  0.609
  0.609
  0.609
  0.609
  0.609
  0.609
  0.609
  0.609
  0.609
  0.609
  0.609
  0.609
  0.609

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  81
  73
  124
  196
  293
  422
  588
  796
  1,052
  1,359
  1,722
  2,146
  2,627
  3,170
  3,774
  4,440
  5,167
  5,954
  6,800
  7,702
  8,661
  9,674
  10,741
  11,861
  13,033
  14,257
  15,533
  16,862
  18,245
  19,683
  21,177
Depreciation, amort., depletion, $m
  2
  6
  6
  8
  9
  11
  14
  18
  22
  27
  33
  36
  44
  53
  64
  75
  87
  100
  114
  129
  145
  162
  180
  199
  219
  239
  261
  283
  306
  330
  356
Funds from operations, $m
  44
  79
  131
  203
  302
  433
  602
  814
  1,073
  1,386
  1,755
  2,182
  2,671
  3,223
  3,838
  4,515
  5,254
  6,054
  6,914
  7,832
  8,806
  9,837
  10,921
  12,060
  13,251
  14,496
  15,794
  17,145
  18,551
  20,013
  21,533
Change in working capital, $m
  -9
  9
  13
  18
  25
  33
  42
  53
  65
  79
  93
  108
  123
  139
  155
  170
  186
  201
  216
  231
  245
  259
  273
  287
  300
  313
  327
  340
  354
  368
  383
Cash from operations, $m
  53
  70
  118
  185
  277
  400
  560
  760
  1,008
  1,307
  1,662
  2,074
  2,548
  3,084
  3,683
  4,344
  5,068
  5,853
  6,697
  7,601
  8,561
  9,577
  10,648
  11,773
  12,951
  14,183
  15,467
  16,805
  18,197
  19,645
  21,150
Maintenance CAPEX, $m
  0
  -1
  -2
  -2
  -4
  -5
  -7
  -10
  -14
  -18
  -23
  -29
  -36
  -44
  -53
  -64
  -75
  -87
  -100
  -114
  -129
  -145
  -162
  -180
  -199
  -219
  -239
  -261
  -283
  -306
  -330
New CAPEX, $m
  -16
  -12
  -17
  -23
  -32
  -42
  -54
  -68
  -83
  -100
  -118
  -138
  -157
  -177
  -198
  -218
  -238
  -257
  -277
  -295
  -314
  -332
  -349
  -366
  -384
  -401
  -418
  -435
  -453
  -471
  -489
Cash from investing activities, $m
  -46
  -13
  -19
  -25
  -36
  -47
  -61
  -78
  -97
  -118
  -141
  -167
  -193
  -221
  -251
  -282
  -313
  -344
  -377
  -409
  -443
  -477
  -511
  -546
  -583
  -620
  -657
  -696
  -736
  -777
  -819
Free cash flow, $m
  7
  58
  99
  159
  242
  353
  498
  682
  911
  1,189
  1,521
  1,908
  2,355
  2,863
  3,432
  4,063
  4,756
  5,509
  6,321
  7,191
  8,118
  9,100
  10,137
  11,226
  12,369
  13,563
  14,810
  16,109
  17,461
  18,868
  20,330
Issuance/(repayment) of debt, $m
  0
  38
  55
  77
  105
  139
  179
  224
  275
  331
  391
  454
  519
  585
  652
  718
  784
  849
  912
  974
  1,034
  1,093
  1,151
  1,208
  1,265
  1,321
  1,378
  1,435
  1,493
  1,552
  1,613
Issuance/(repurchase) of shares, $m
  -33
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  -34
  38
  55
  77
  105
  139
  179
  224
  275
  331
  391
  454
  519
  585
  652
  718
  784
  849
  912
  974
  1,034
  1,093
  1,151
  1,208
  1,265
  1,321
  1,378
  1,435
  1,493
  1,552
  1,613
Total cash flow (excl. dividends), $m
  -26
  95
  154
  236
  347
  492
  677
  906
  1,186
  1,520
  1,911
  2,361
  2,873
  3,447
  4,084
  4,781
  5,540
  6,357
  7,233
  8,165
  9,152
  10,194
  11,288
  12,435
  13,634
  14,884
  16,187
  17,544
  18,954
  20,420
  21,944
Retained Cash Flow (-), $m
  -61
  -59
  -85
  -120
  -163
  -216
  -278
  -349
  -429
  -516
  -609
  -706
  -808
  -911
  -1,015
  -1,119
  -1,221
  -1,322
  -1,421
  -1,517
  -1,611
  -1,703
  -1,793
  -1,882
  -1,970
  -2,058
  -2,146
  -2,234
  -2,325
  -2,417
  -2,512
Prev. year cash balance distribution, $m
 
  53
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  89
  69
  116
  184
  276
  398
  557
  758
  1,005
  1,303
  1,655
  2,066
  2,537
  3,069
  3,663
  4,319
  5,035
  5,812
  6,648
  7,541
  8,491
  9,495
  10,553
  11,664
  12,827
  14,042
  15,309
  16,629
  18,003
  19,431
Discount rate, %
 
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
 
  86
  63
  101
  151
  214
  289
  376
  474
  577
  683
  786
  881
  964
  1,030
  1,075
  1,097
  1,096
  1,070
  1,024
  958
  878
  788
  692
  594
  499
  410
  329
  257
  197
  146
Current shareholders' claim on cash, %
  100
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0

Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban to treat heparin-induced thrombocytopenia; Ryanodex injectable suspension for the treatment of malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for the treatment of breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and diclofenac-misoprostol. It develops EP-3101, a bendamustine ready to dilute (RTD) liquid; EP-3102, a bendamustine short infusion time RTD liquid for the treatment of chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma; and EP-4104, a dantrolene for the treatment of exertional heat stroke. The company also develops EP-5101 (pemetrexed) as RTD liquid, which is in pre-clinical formulation and toxicology studies to treat lung cancer and mesothelioma; and EP-6101, a bivalirudin RTU liquid formulation for the treatment of percutaneous transluminal angioplasty. Eagle Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Woodcliff Lake, New Jersey.

FINANCIAL RATIOS  of  Eagle Pharmaceuticals (EGRX)

Valuation Ratios
P/E Ratio 10
Price to Sales 4.3
Price to Book 5.4
Price to Tangible Book
Price to Cash Flow 15.3
Price to Free Cash Flow 21.9
Growth Rates
Sales Growth Rate 186.4%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 700%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets 47.8%
Ret/ On Assets - 3 Yr. Avg. 0.2%
Return On Total Capital 67.2%
Ret/ On T. Cap. - 3 Yr. Avg. -10.3%
Return On Equity 67.2%
Return On Equity - 3 Yr. Avg. -10.3%
Asset Turnover 1.1
Profitability Ratios
Gross Margin 70.9%
Gross Margin - 3 Yr. Avg. 61.7%
EBITDA Margin 29.1%
EBITDA Margin - 3 Yr. Avg. -22.1%
Operating Margin 28%
Oper. Margin - 3 Yr. Avg. -23%
Pre-Tax Margin 28%
Pre-Tax Margin - 3 Yr. Avg. -22.5%
Net Profit Margin 42.9%
Net Profit Margin - 3 Yr. Avg. -15.8%
Effective Tax Rate -52.8%
Eff/ Tax Rate - 3 Yr. Avg. -15.9%
Payout Ratio 0%

EGRX stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the EGRX stock intrinsic value calculation we used $189 million for the last fiscal year's total revenue generated by Eagle Pharmaceuticals. The default revenue input number comes from 2016 income statement of Eagle Pharmaceuticals. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our EGRX stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for EGRX is calculated based on our internal credit rating of Eagle Pharmaceuticals, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Eagle Pharmaceuticals.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of EGRX stock the variable cost ratio is equal to 58.7%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $26 million in the base year in the intrinsic value calculation for EGRX stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 3.5% for Eagle Pharmaceuticals.

Corporate tax rate of 27% is the nominal tax rate for Eagle Pharmaceuticals. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the EGRX stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for EGRX are equal to 10.1%.

Life of production assets of 19.5 years is the average useful life of capital assets used in Eagle Pharmaceuticals operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for EGRX is equal to 7.9%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $151 million for Eagle Pharmaceuticals - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 15.215 million for Eagle Pharmaceuticals is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Eagle Pharmaceuticals at the current share price and the inputted number of shares is $0.8 billion.

RELATED COMPANIES Price Int.Val. Rating
MDCO Medicines 37.95 1.43  str.sell
NVS Novartis ADR 84.97 35.73  str.sell
TEVA Teva Pharmaceu 32.45 70.59  str.buy
CELG Celgene 134.15 113.99  hold
PFE Pfizer 33.00 28.58  hold
MGNX Macrogenics 16.87 1.91  str.sell
MRK Merck&Co 63.69 30.02  str.sell
LLY Eli Lilly 83.02 94.86  hold
INFI Infinity Pharm 1.33 0.36  str.sell

COMPANY NEWS

▶ 3 Stocks the Smartest Investors Are Buying Right Now   [Jul-20-17 01:30PM  Motley Fool]
▶ Key FDA Events to Watch Out for in Jul 2017   [Jul-03-17 08:13AM  Zacks]
▶ These 3 Stocks Are Up Over 500% in the Last 3 Years   [Jun-25-17 09:42AM  Motley Fool]
▶ Teva Pharma, Eagle Pharma, Depomed Among Slew Getting Price Haircuts   [May-25-17 04:10PM  Investor's Business Daily]
▶ Biotech And Pharma Industry And Stock News   [01:38PM  Investor's Business Daily]
▶ Eagle Pharmaceuticals posts 1Q profit   [May-08-17 06:56AM  Associated Press]
▶ 3 Top Biotech Stocks to Buy in 2017   [Mar-26-17 06:43AM  Motley Fool]
▶ New Strong Sell Stocks for March 6th   [Mar-06-17 10:10AM  Zacks]
▶ Eagle Pharmaceuticals posts 4Q profit   [07:04AM  Associated Press]
▶ Eagle Pharmaceuticals Pemetrexed NDA Submitted for Review   [Jan-03-17 06:50AM  Business Wire]
▶ Hedge Funds Arent Crazy About Photronics, Inc. (PLAB) Anymore   [Dec-05-16 02:04AM  at Insider Monkey]
Stock chart of EGRX Financial statements of EGRX Annual reports of EGRX
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

VALUATION THEORY       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2017. All rigths reserved.